



**Karolinska
Institutet**

Institutionen för molekylär medicin och kirurgi

**GENETIC AND EPIGENETIC STUDIES OF DIABETES AND
DIABETIC NEPHROPATHY WITH FOCUS ON THE IGF-IGFBP
AXIS**

AKADEMISK AVHANDLING

som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentlig försvaras i
Rolf Luft Auditorium, L1:00, Karolinska Universitetssjukhuset, Solna, Stockholm

Fredagen den 29 augusti, 2014, kl 09.00

av

Tianwei Gu

Huvudhandledare:

Professor Kerstin Brismar
Institutionen för molekylär medicin och kirurgi
Karolinska Institutet

Fakultetsopponent:

Professor Peter Bang
Institutionen för klinisk och experimentell
medicin
Linköping Universitet

Bihandledare:

Associate Professor Harvest F Gu
Institutionen för molekylär medicin och kirurgi
Karolinska Institutet

Betygsnämnd:

Professor Anna Krook
Institutionen för fysiologi och farmakologi
Karolinska Institutet

Professor Dan Holmberg
Institutionen för experimentell medicinsk
vetenskap
Lunds Universitet

Associate Professor Leonid Padyukov
Institutionen för medicin, centrum för
molekylär medicin
Karolinska Institutet

Stockholm 2014

Abstract

Diabetes and diabetic nephropathy (DN) are complex diseases reflecting a complex interplay between genetic and non-genetic factors. The insulin-like growth factor (IGF) - IGF binding protein (IGFBP) axis plays an important role in the development of diabetes and DN. Recent reports have demonstrated that genetic polymorphisms in this axis are associated with diabetes and DN. However, the information of epigenetic study is very limited. In this study, we selected four genes from this axis including *IGF1*, *IGF2*, *IGFBP1* and *IGF2BP2* to evaluate their genetic and epigenetic associations with diabetes and DN. In parallel, we analyzed the serum protein levels.

SNP rs35767 in the *IGF1* gene promoter region has been reported to be associated with insulin resistance and circulating IGF-I levels. **In Study I**, we analyzed *IGF1* DNA methylation levels at CpG sites in the promoter region including this SNP and measured serum IGF-I concentration in Swedish subjects with normal glucose tolerance (NGT) or type 2 diabetes (T2D). Data suggested that increased DNA methylation in the gene promoter and decreased circulating IGF-I levels are associated with T2D.

IGFBP-1 is produced in liver and mainly regulated by insulin. Clinical observations have demonstrated that high levels of circulating IGFBP-1 are associated with T1D, while low serum levels are associated with the risk of T2D. There is a CpG island at the promoter and 5'-untranslated region (5'-UTR) of the *IGFBP1* gene. We analyzed *IGFBP1* DNA methylation levels in Swedish T2D patients (**Study II**) and T1D patients with or without DN (**Study III**). Results demonstrated that *IGFBP1* DNA methylation levels were decreased in T1D patients but increased in T2D patients in comparison with NGT subjects. Furthermore, decreased and increased IGFBP-1 serum levels were respectively associated with T2D and T1D.

The *IGF2BP2* gene is located on chromosome 3q27.2 within a region linked to diabetes and DN. The protein encoded *IGF2BP2* binds to 5'-UTR of the imprinting *IGF2* gene, which is located on chromosome 11p15.5. In **Study IV**, we genotyped SNPs rs10770125 (A/G) and rs4402960 (G/T) in the *IGF2* and *IGF2BP2* genes respectively. Diabetes patients with or without DN and NGT subjects from GoKinD, Czech and Swedish populations were enrolled in this study. Data showed that the *IGF2BP2* polymorphism rs4402960 was associated with T2D. This *IGF2BP2* polymorphism and rs10770125 in the *IGF2* gene were found to be associated with DN in male T1D patients.

In conclusion, our studies provide evidence that the *IGF1*, *IGF2*, *IGFBP1* and *IGF2BP2* genes have genetic and epigenetic effects in diabetes and DN. To better understand the importance of our findings, further investigations of tissue specific DNA methylation levels and their impacts on translated proteins are needed.